Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery?
Covered in this story
What has happened since
- Merck & Co. is down 6.3% since this was published, 46 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Merck & Co.
- Scotiabank: $149 → $180 by Sep 2027 · sector outperform via marketbeat.com
- Argus Research: $130 → $145 by Aug 2027 · Buy via GuruFocus
- Guggenheim: $128 → $146 by Aug 2027 · buy via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 33 stories mentioning Merck & Co., the earliest published 18 Jun 2026.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.